{{Infobox company | name = Array BioPharma | type = Subsidiary | traded_as = {{NASDAQ was|ARRY}} | industry = Oncology<BR>Medication | founded = {{start date and age|1998}} | founder = {{ubl|Drs. Tony Piscopio|Kevin Koch|David Snitman|K.C. Nicolaou}} | hq_location_city = Boulder, Colorado | hq_location_country = United States | revenue = $173.8 million (2018) | parent = Pfizer | website = {{URL|https://www.arraybiopharma.com/}} }} '''Array BioPharma''' is an American clinical stage, pharmaceutical company that focuses on oncology medication headquartered in Boulder, Colorado. The company is currently a subsidiary of Pfizer after being acquired for $11 billion in 2019.
==History== In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.<ref>{{Cite web|title=Co-Founder Of Array BioPharma, Inc. To Lead New Korean Out-Sourcing Chemistry Company|url=https://www.biospace.com/article/co-founder-of-array-biopharma-inc-to-lead-new-korean-out-sourcing-chemistry-company-/|access-date=2020-07-28|website=BioSpace|language=en-US}}</ref>
In November 2000, the company became a public company via an initial public offering.<ref>{{cite news | url=https://money.cnn.com/2000/11/17/deals/ipos/ | archive-url=https://web.archive.org/web/20190810125456/https://money.cnn.com/2000/11/17/deals/ipos/ | url-status=dead | archive-date=August 10, 2019 | title=Array IPO up 17% | work=CNN | date=November 17, 2000}}</ref>
In June 2019, Pfizer acquired the company for approximately $11 billion.<ref>{{Cite web|title=Pfizer acquires Array BioPharma, valued at $11.4 billion|url=https://www.rappler.com/business/233335-pfizer-acquisition-array-biopharma/|access-date=2020-07-29|website=Rappler|date=18 June 2019 |language=en}}</ref>
== Discovery of FDA Approved Small Molecules ==
* '''MEKTOVI''' (Binimetinib) - selective MEK inhibitor - Approved 2018, acquired by Pfizer * '''TUKYSA''' (Tucatinib) - HER2 inhibitor - Approved 2020, owned by Seagen (Seattle Genetics) * '''BRAFTOVI''' (Encorafenib) - BRAF inhibitor - Approved 2018, acquired by Pfizer * '''KRAZATI''' (Adagrasib) - KRasG12C mutation inhibitor - Approved 2022, collaboration with Mirati Therapeutics * '''KOSELUGO''' (Selumetinib) - MEK1/2 inhibitor - Approved 2020, licensed by Astrazeneca * '''VITRAKVI''' (Larotrectinib) - TRK Inhibitor - Approved 2018, licensed by Loxo Oncology (Eli Lilly) * '''[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-medullary-thyroid-cancer-ret-mutation#:~:text=On%20September%2027%2C%202024%2C%20the,an%20FDA%2Dapproved%20test%2C%20who RETEVMO]''' (Selpercatinib) - RET inhibitor - Approved 2024, licensed by Loxo Oncology (Eli Lilly) * '''GANOVO''' (Danoprevir) - HCV Protease inhibitor - [https://pmc.ncbi.nlm.nih.gov/articles/PMC7368560/ Approved] 2018 (in China), licensed by Roche
==References== {{Reflist}}
{{Authority control}}
Category:1998 establishments in Colorado Category:2000 initial public offerings Category:2019 mergers and acquisitions Category:American companies established in 1998 Category:Pharmaceutical companies established in 1998 Category:Biotechnology companies established in 1998 Category:Pharmaceutical companies of the United States Category:Companies formerly listed on the Nasdaq Category:Biotechnology companies of the United States Category:Health care companies based in Colorado Category:Companies based in Boulder, Colorado Category:Pfizer Category:Pharmaceutical companies